d-Penicillamine therapy in patients with HBsAg-negative chronic active hepatitis and major prednisolone-induced adverse effects
- 1 November 1990
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 11 (3) , 322-325
- https://doi.org/10.1016/0168-8278(90)90215-d
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- ANTIBODIES TO LIVER-SPECIFIC PROTEIN PREDICT OUTCOME OF TREATMENT WITHDRAWAL IN AUTOIMMUNE CHRONIC ACTIVE HEPATITISThe Lancet, 1984
- Controlled trial of D-penicillamine with low dosis in the treatment of chronic liver diseasesGastroenterologia Japonica, 1980
- Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis.Gut, 1980
- Controlled trial of synthetic D-penicillamine and prednisone in maintenance therapy for active chronic hepatitis.Gut, 1977
- Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared.Gut, 1975
- Synthetic D(-)penicillamine in rheumatoid arthritis. Double-blind controlled study of a high and low dosage regimen.Annals of the Rheumatic Diseases, 1975